Moderna’s Shift to Cancer Company Lifts Stock Up 177%
The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.
The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else. This story matters for General News readers tracking general. Reported by nytimes.com. Read the full original at the source link below.
Originally reported by nytimes.com. NewsDebate curates and briefs the general news stories that matter. Our editorial policy →